Brown E Sherwood, Murray Michelle, Carmody Thomas J, Kennard Beth D, Hughes Carroll W, Khan David A, Rush A John
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas 75390-8849, USA.
Ann Allergy Asthma Immunol. 2008 May;100(5):433-8. doi: 10.1016/S1081-1206(10)60467-X.
Despite the high co-occurrence between depression and asthma, few studies have addressed methods assessing the severity of depressive symptoms among patients with asthma.
To evaluate the psychometric properties of the Quick Inventory of Depressive Symptomatology-Self-report (QIDS-SR16), a 16-item measure of depressive symptom severity, in patients with asthma.
The psychometric properties of the QIDS-SR16 were compared at treatment exit with those of the 30-item self-report Inventory of Depressive Symptomatology (IDS-SR30) and the 17-item clinician-rated Hamilton Rating Scale for Depression (HRSD17) in 73 outpatients with asthma who were treated with citalopram or placebo for nonpsychotic major depressive disorder. Correlations between the depression rating scales and the Mini Asthma Quality of Life Questionnaire were calculated.
Internal consistency at exit was strong for the QIDS-SR16 (Cronbach alpha values are .87 for the QIDS-SR16, .95 for the IDS-SR30, and .87 for the HRSD17). The QIDS-SR16 and HRSD17 total scores were highly correlated (r = 0.85), as were the QIDS-SR16 and IDS-SR30 total scores (r = 0.97). All QIDS-SR16 item total score correlations were significant (P < .001). The QIDS-SR16, IDS-SR30, and HRSD17 showed comparable sensitivity to symptom change, indicating high concurrent validity for all 3 scales. The total QIDS-SR16 baseline to exit change score demonstrated a significant negative correlation (r = -0.49, P < .001) with the Mini Asthma Quality of Life Questionnaire. Thus, greater depressive symptom severity was associated with lower asthma-related quality of life.
The QIDS-SR16 showed good reliability and impressive construct validity. Strong psychometric properties of this brief self-report format and its sensitivity to treatment change suggest that the QIDS-SR16 is a valuable clinical tool.
尽管抑郁症和哮喘经常同时出现，但很少有研究探讨评估哮喘患者抑郁症状严重程度的方法。
评估用于测量抑郁症状严重程度的16项自评量表——快速抑郁症状自评量表（QIDS-SR16）在哮喘患者中的心理测量特性。
在治疗结束时，将73例接受西酞普兰或安慰剂治疗非精神病性重度抑郁症的哮喘门诊患者的QIDS-SR16的心理测量特性与30项自评抑郁症状量表（IDS-SR30）和17项临床医生评定的汉密尔顿抑郁评定量表（HRSD17）进行比较。计算抑郁评定量表与哮喘生活质量简明问卷之间的相关性。
治疗结束时，QIDS-SR16的内部一致性较强（QIDS-SR16的Cronbach α值为0.87，IDS-SR30为0.95，HRSD17为0.87）。QIDS-SR16与HRSD17的总分高度相关（r = 0.85），QIDS-SR16与IDS-SR30的总分也高度相关（r = 0.97）。所有QIDS-SR16项目与总分的相关性均具有统计学意义（P < .001）。QIDS-SR16、IDS-SR30和HRSD17对症状变化的敏感性相当，表明这三个量表具有较高的同时效度。QIDS-SR16从基线到治疗结束的总分变化与哮喘生活质量简明问卷呈显著负相关（r = -0.49，P < .001）。因此，抑郁症状越严重，哮喘相关生活质量越低。
QIDS-SR16具有良好的信度和令人印象深刻的结构效度。这种简短自评形式的强大心理测量特性及其对治疗变化的敏感性表明，QIDS-SR16是一种有价值的临床工具。
